This article was originally published in The Gray Sheet
Susan Walden, forrmer Washington representative for Johnson & Johnson and counsel and state government affairs specialist with the Nonprescription Drug Manufacturers Association, sets up an independent D.C.-based government affairs office for representation in the pharmaceutical and medical device fields...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.